Inactive Instrument
Allied Corp. Stock Other OTC
Stocks
ALID
US0191141078
Pharmaceuticals
OTC Markets Traded| Market Cap | 1.3M 1.14M 1.05M 986K 1.85M 123M 1.89M 12.66M 4.9M 60.78M 4.9M 4.79M 211M | P/E 2023 |
-2.13x | P/E 2024 | -2.52x |
|---|---|---|---|---|---|
| Enterprise Value | 7.55M 6.62M 6.1M 5.71M 10.71M 712M 10.94M 73.35M 28.38M 352M 28.35M 27.74M 1.22B | EV / Sales 2023 |
394,366,816x | EV / Sales 2024 | 171,944,593x |
| Free-Float |
52.84% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -5.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
Radka Milanova
CTO | Chief Tech/Sci/R&D Officer | 71 | - |
James Smeeding
PRN | Corporate Officer/Principal | - | 2020-05-01 |
| Director | Title | Age | Since |
|---|---|---|---|
James Smeeding
BRD | Director/Board Member | - | 2020-05-01 |
| Director/Board Member | - | - | |
Abdul Nnyenje
BRD | Director/Board Member | - | 2024-10-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -5.00% | -5.00% | - | - | 117 | ||
| +3.89% | +0.71% | +329.09% | +17.12% | 2.64B | ||
| +5.52% | -10.99% | +155.40% | +127.02% | 1.73B | ||
| +0.43% | -9.89% | -18.85% | +135.33% | 459M | ||
| 0.00% | +6.67% | +23.08% | -4.00% | 51.65M | ||
| Average | +0.97% | -3.08% | +122.18% | +68.87% | 1.22B | |
| Weighted average by Cap. | +4.10% | -3.53% | +231.50% | +67.00% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 0.07 0.06 0.06 0.05 0.1 6.8 0.1 0.7 0.27 3.36 0.27 0.26 11.66 | 0.1 0.08 0.08 0.07 0.14 9.07 0.14 0.93 0.36 4.48 0.36 0.35 15.55 |
| Net income | -10.68M -9.36M -8.63M -8.08M -15.15M -1.01B -15.46M -104M -40.13M -498M -40.09M -39.21M -1.73B | -3.98M -3.49M -3.21M -3.01M -5.64M -375M -5.76M -38.62M -14.95M -185M -14.93M -14.6M -643M |
| Net Debt | 5.65M 4.96M 4.57M 4.28M 8.02M 533M 8.19M 54.9M 21.24M 263M 21.22M 20.76M 914M | 6.25M 5.48M 5.05M 4.73M 8.86M 589M 9.05M 60.69M 23.48M 291M 23.46M 22.95M 1.01B |
Employees
-
Sector
Pharmaceuticals
















